New injection shows promise for controlling high blood pressure

NCT ID NCT04936035

Completed Disease control Sponsor: Alnylam Pharmaceuticals Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested a new medicine called ALN-AGT01 in 394 adults with mild-to-moderate high blood pressure. The goal was to see if it could safely lower blood pressure over three months. Participants received either the drug or a placebo, and blood pressure was measured continuously over 24 hours. The study has been completed, and results will help determine if this approach can help manage hypertension long-term.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

benign essential hypertension hypertensive disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HYPERTENSION

Contacts and locations

Show contact details

Locations

Clinical Trial Site

Birmingham, Alabama, 35209, United States
Clinical Trial Site

Tempe, Arizona, 85281, United States
Clinical Trial Site

Tempe, Arizona, 85282, United States
Clinical Trial Site

Beverly Hills, California, 90211, United States
Clinical Trial Site

La Mesa, California, 91942, United States
Clinical Trial Site

Los Angeles, California, 90057, United States
Clinical Trial Site

San Diego, California, 92103, United States
Clinical Trial Site

South Gate, California, 90280, United States
Clinical Trial Site

Vista, California, 92083, United States
Clinical Trial Site

Washington D.C., District of Columbia, 20011, United States
Clinical Trial Site

Clearwater, Florida, 33756, United States
Clinical Trial Site

Coral Gables, Florida, 33134, United States
Clinical Trial Site

Fleming Island, Florida, 32003, United States
Clinical Trial Site

Hollywood, Florida, 33021, United States
Clinical Trial Site

Hollywood, Florida, 33024, United States
Clinical Trial Site

Inverness, Florida, 34452, United States
Clinical Trial Site

Jacksonville, Florida, 32204, United States
Clinical Trial Site

Jacksonville, Florida, 32216, United States
Clinical Trial Site

Jacksonville, Florida, 32256, United States
Clinical Trial Site

Miami, Florida, 33126, United States
Clinical Trial Site

Miami, Florida, 33135, United States
Clinical Trial Site

Naples, Florida, 34102, United States
Clinical Trial Site

Orlando, Florida, 32801, United States
Clinical Trial Site

Acworth, Georgia, 30101, United States
Clinical Trial Site

Columbus, Georgia, 31904, United States
Clinical Trial Site

Fayetteville, Georgia, 30214, United States
Clinical Trial Site

Macon, Georgia, 31210, United States
Clinical Trial Site

Champaign, Illinois, 61822, United States
Clinical Trial Site

Valparaiso, Indiana, 46383, United States
Clinical Trial Site

West Des Moines, Iowa, 50266, United States
Clinical Trial Site

Lake Charles, Louisiana, 70601, United States
Clinical Trial Site

New Orleans, Louisiana, 70124, United States
Clinical Trial Site

Prairieville, Louisiana, 70769, United States
Clinical Trial Site

Baltimore, Maryland, 21229, United States
Clinical Trial Site

Jackson, Mississippi, 39209, United States
Clinical Trial Site

Jefferson City, Missouri, 65109, United States
Clinical Trial Site

Las Vegas, Nevada, 89119, United States
Clinical Trial Site

New York, New York, 10036, United States
Clinical Trial Site

The Bronx, New York, 10456, United States
Clinical Trial Site

Greensboro, North Carolina, 27408, United States
Clinical Trial Site

Greensboro, North Carolina, 27410, United States
Clinical Trial Site

Medford, Oregon, 97504, United States
Clinical Trial Site

Greenville, South Carolina, 29607, United States
Clinical Trial Site

Memphis, Tennessee, 38119, United States
Clinical Trial Site

Cedar Park, Texas, 78613, United States
Clinical Trial Site

Houston, Texas, 77074, United States
Clinical Trial Site

Houston, Texas, 77081, United States
Clinical Trial Site

Magnolia, Texas, 77355, United States
Clinical Trial Site

Pearland, Texas, 77584, United States
Clinical Trial Site

San Antonio, Texas, 78229, United States
Clinical Trial Site

Stephenville, Texas, 76401, United States
Clinical Trial Site

Tomball, Texas, 77375, United States
Clinical Trial Site

Waco, Texas, 76708, United States
Clinical Trial Site

Burke, Virginia, 22015, United States
Clinical Trial Site

Red Deer, Alberta, Canada
Clinical Trial Site

New Minas, Nova Scotia, Canada
Clinical Trial Site

Brampton, Ontario, Canada
Clinical Trial Site

Toronto, Ontario, Canada
Clinical Trial Site

Chicoutimi, Quebec, Canada
Clinical Trial Site

Mirabel, Quebec, Canada
Clinical Trial Site

Montreal, Quebec, Canada
Clinical Trial Site

Québec, Quebec, Canada
Clinical Trial Site

Trois-Rivières, Quebec, Canada
Clinical Trial Site

Victoriaville, Quebec, Canada
Clinical Trial Site

Bayamón, 00961, Puerto Rico
Clinical Trial Site

Ponce, 00716, Puerto Rico
Clinical Trial Site

San Juan, Puerto Rico
Clinical Trial Site

Ivano-Frankivsk, Ukraine
Clinical Trial Site

Kharkiv, Ukraine
Clinical Trial Site

Odesa, Ukraine
Clinical Trial Site

Uzhhorod, Ukraine
Clinical Trial Site

Glasgow, United Kingdom
Clinical Trial Site

Hexham, United Kingdom
Clinical Trial Site

London, United Kingdom
Clinical Trial Site

Manchester, United Kingdom